Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings Of The Fortnight: Despite Venture Capital Fundraising Struggles, Deals Continue

This article was originally published in The Pink Sheet Daily

Executive Summary

Big venture rounds for Flexion and Lux Biosciences highlight the last two weeks' financing activity.

You may also be interested in...



Lux Bioscience Brings In $50 Million To Take Luveniq To The Finish Line Alone

The ophthalmology specialist's inside round could take it through to launch of its lead product--or act as leverage in deal negotiations.

Amarin Moves Beyond Bridge Financing With $70 Million Private Placement

Existing and new investors are drawn by the potential of a compound that would compete with statins in the dyslipidemia market.

Venture Eyes Ophthalmology--And Likes What It Sees

Ophthalmology has long been a bright spot for venture investors given the potential market size, health care burden, and high unmet medical need associated with many eye diseases. Based on a recent analysis by Start-Up magazine, there is no sign that trend is diminishing. Using Elsevier's Strategic Transactions database, Start-Up found that private backers have poured nearly $1.8 billion into 58 ophthalmology start-ups since 1999, with the money split nearly 50/50 in terms of device and drug investments. This trend is likely to accelerate as a number of new acquirers emerge to play in what was once a niche area.

Related Content

Topics

UsernamePublicRestriction

Register

PS068644

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel